David M Mannino1, Enrique Diaz-Guzman2. 1. Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY; Department of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky College of Medicine, Lexington, KY. Electronic address: dmannino@uky.edu. 2. Department of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky College of Medicine, Lexington, KY.
Abstract
BACKGROUND: The GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages for COPD use a fixed ratio of the postbronchodilator FEV(1)/FVC ratio of 0.70 as a threshold to define obstruction. Others advocate using the lower limit of normal (LLN) for the FEV(1)/FVC ratio, FEV(1), and FVC to define abnormality. This study investigated mortality in a representative sample of the US adult population with COPD by comparing abnormality determined using GOLD criteria to that determined using LLN criteria. METHODS: We used baseline data from the Third National Health and Nutrition Examination Survey and follow-up mortality data. We classified subjects as obstructed, restricted, or normal based on GOLD vs LLN criteria and used Cox proportional hazards models to determine the relation between lung function impairment and mortality, adjusting for covariates. RESULTS: The study sample included 13,847 subjects, of whom 3,774 died during the follow-up period. Of subjects classified as obstructed and restricted using GOLD criteria, 20.9% and 18.0%, respectively, were classified as normal using LLN criteria. Compared with people with normal lung function, mortality was increased in the obstructed (hazard ratio, 1.46; 95% CI, 1.21-1.86) and restricted (hazard ratio, 1.94; 95% CI, 1.58-2.39) subjects classified as normal using the LLN. CONCLUSIONS: In the nationally representative Third National Health and Nutrition Examination Survey data, subjects classified as normal using LLN criteria but obstructed or restricted using GOLD criteria have a higher risk of mortality.
BACKGROUND: The GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages for COPD use a fixed ratio of the postbronchodilator FEV(1)/FVC ratio of 0.70 as a threshold to define obstruction. Others advocate using the lower limit of normal (LLN) for the FEV(1)/FVC ratio, FEV(1), and FVC to define abnormality. This study investigated mortality in a representative sample of the US adult population with COPD by comparing abnormality determined using GOLD criteria to that determined using LLN criteria. METHODS: We used baseline data from the Third National Health and Nutrition Examination Survey and follow-up mortality data. We classified subjects as obstructed, restricted, or normal based on GOLD vs LLN criteria and used Cox proportional hazards models to determine the relation between lung function impairment and mortality, adjusting for covariates. RESULTS: The study sample included 13,847 subjects, of whom 3,774 died during the follow-up period. Of subjects classified as obstructed and restricted using GOLD criteria, 20.9% and 18.0%, respectively, were classified as normal using LLN criteria. Compared with people with normal lung function, mortality was increased in the obstructed (hazard ratio, 1.46; 95% CI, 1.21-1.86) and restricted (hazard ratio, 1.94; 95% CI, 1.58-2.39) subjects classified as normal using the LLN. CONCLUSIONS: In the nationally representative Third National Health and Nutrition Examination Survey data, subjects classified as normal using LLN criteria but obstructed or restricted using GOLD criteria have a higher risk of mortality.
Authors: Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner Journal: JAMA Date: 2019-06-25 Impact factor: 56.272
Authors: Wouter van Dijk; Wan Tan; Pei Li; Best Guo; Summer Li; Andrea Benedetti; Jean Bourbeau Journal: Ann Fam Med Date: 2015 Jan-Feb Impact factor: 5.166
Authors: Chantal Robitaille; Esther Dajczman; Andrew M Hirsch; David Small; Pierre Ernst; Dana Porubska; Mark Palayew Journal: Can Respir J Date: 2015-05-11 Impact factor: 2.409
Authors: Elizabeth C Oelsner; Eric A Hoffman; Aaron R Folsom; J Jeffrey Carr; Paul L Enright; Steven M Kawut; Richard Kronmal; David Lederer; Joao A C Lima; Gina S Lovasi; Steven Shea; R Graham Barr Journal: Ann Intern Med Date: 2014-12-16 Impact factor: 25.391
Authors: Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera Journal: Lung India Date: 2013-07
Authors: Surya P Bhatt; Jessica C Sieren; Mark T Dransfield; George R Washko; John D Newell; Douglas S Stinson; Gideon K D Zamba; Eric A Hoffman Journal: Thorax Date: 2013-03-23 Impact factor: 9.139
Authors: Reinier P Akkermans; Marvin A Berrevoets; Ivo J Smeele; Annelies E Lucas; Bart P Thoonen; Joke G Grootens-Stekelenburg; Yvonne F Heijdra; Chris van Weel; Tjard R Schermer Journal: BMC Pulm Med Date: 2012-03-22 Impact factor: 3.317
Authors: Katherine E Lowe; Elizabeth A Regan; Antonio Anzueto; Erin Austin; John H M Austin; Terri H Beaty; Panayiotis V Benos; Christopher J Benway; Surya P Bhatt; Eugene R Bleecker; Sandeep Bodduluri; Jessica Bon; Aladin M Boriek; Adel Re Boueiz; Russell P Bowler; Matthew Budoff; Richard Casaburi; Peter J Castaldi; Jean-Paul Charbonnier; Michael H Cho; Alejandro Comellas; Douglas Conrad; Corinne Costa Davis; Gerard J Criner; Douglas Curran-Everett; Jeffrey L Curtis; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Jennifer G Dy; Ashraf Fawzy; Margaret Fleming; Eric L Flenaugh; Marilyn G Foreman; Spyridon Fortis; Hirut Gebrekristos; Sarah Grant; Philippe A Grenier; Tian Gu; Abhya Gupta; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Lystra P Hayden; Craig P Hersh; Brian D Hobbs; Eric A Hoffman; James C Hogg; John E Hokanson; Karin F Hoth; Albert Hsiao; Stephen Humphries; Kathleen Jacobs; Francine L Jacobson; Ella A Kazerooni; Victor Kim; Woo Jin Kim; Gregory L Kinney; Harald Koegler; Sharon M Lutz; David A Lynch; Neil R MacIntye; Barry J Make; Nathaniel Marchetti; Fernando J Martinez; Diego J Maselli; Anne M Mathews; Meredith C McCormack; Merry-Lynn N McDonald; Charlene E McEvoy; Matthew Moll; Sarah S Molye; Susan Murray; Hrudaya Nath; John D Newell; Mariaelena Occhipinti; Matteo Paoletti; Trisha Parekh; Massimo Pistolesi; Katherine A Pratte; Nirupama Putcha; Margaret Ragland; Joseph M Reinhardt; Stephen I Rennard; Richard A Rosiello; James C Ross; Harry B Rossiter; Ingo Ruczinski; Raul San Jose Estepar; Frank C Sciurba; Jessica C Sieren; Harjinder Singh; Xavier Soler; Robert M Steiner; Matthew J Strand; William W Stringer; Ruth Tal-Singer; Byron Thomashow; Gonzalo Vegas Sánchez-Ferrero; John W Walsh; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Gloria Westney; Ava Wilson; Robert A Wise; Andrew Yen; Kendra Young; Jeong Yun; Edwin K Silverman; James D Crapo Journal: Chronic Obstr Pulm Dis Date: 2019-11